Sandoz has received German marketing authorization for the AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD, the company has announced. The German approval is for the 50/500 µg version of the inhaler. Denmark approved both the 50/250 µg and 50/500 µg versions of the product in December 2013.
The German authorization triggers a $2 million milestone payment from Sandoz to Vectura, which developed the product (formerly known as VR-315).
Vectura CEO Chris Blackwell said, “This approval further de-risks our high value respiratory generic portfolio in Europe and the rest of the world and, provides a significant cash milestone to Vectura. Once launched, the royalty stream from AirFluSal Forspiro will contribute to Vectura’s differentiated top line growth.”
Read the Sandoz press release.
